Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Ensysce Biosciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
3.93
3.53
2.52
2.23
5.21
5.07
Research and development
4.39
4.69
19.8
7.59
7.22
10.4
Selling, general and administrative
1.15
18.7
General and administrative
18.7
6.91
5.36
4.72
4.93
Operating expenses
1.56
3.33
5.54
23.4
26.7
12.9
11.9
15.3
Operating income
-0.96
-3.33
-1.61
-19.9
-24.2
-10.7
-6.73
-10.2
Interest expense
1
1.3
0.11
0.35
1.29
0.02
Interest income
3.63
4.25
0.72
Other non-operating income
1.45
-9.28
0.01
0.09
-1.26
0.06
Pre-tax income
2.68
-0.51
4.56
Income tax
0.55
0.56
0.24
Net income to minority interests
-0.22
-0.06
-0.04
-0.01
-0
-0
Net income
2.12
-1.07
4.31
-29.9
-25.1
-10.6
-7.99
-10.2
EBITDA
-1.61
-19.9
-24.2
-10.7
-6.73
-10.2
EPS, basic
-3.15
-9.46
0.00
-444.92
-2,093.00
-70.40
-11.45
-3.98
EPS, diluted
-3.15
-9.46
0.00
-22.22
-2,093.00
-70.40
-11.45
-3.98
Shares, basic (weighted)
0.44
0.44
1.05
0.07
0.01
0.15
0.7
2.56
Shares, diluted (weighted)
0.44
0.44
1.1
1.34
0.01
0.15
0.7
2.56
Balance sheet
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
1.66
1.06
0.19
12.3
3.15
1.12
3.5
4.31
Other current assets
0.09
0.16
2.93
1.85
0.02
0.02
0.02
Total current assets
1.92
1.2
0.35
15.7
5.3
2.29
5.34
7.25
Property, plant and equipment
0
0.12
Lease right-of-use assets
0.02
Other non-current assets
0
0.75
0.59
0.42
0.25
0.08
Total assets
205
197
0.35
16.4
5.89
2.71
5.6
7.45
Accounts payable
0.43
2.77
1.72
0.3
2.94
1.94
1.36
3.27
Accrued liabilities
0.01
Total current liabilities
0.44
2.77
7.01
16.5
9.46
3.33
2.21
4.57
Long-term debt
0.57
0.57
4.44
0.14
Other non-current liabilities
3.65
0.31
0.03
0.01
Total liabilities
13.2
17.5
7.01
24.6
9.91
3.36
2.22
4.57
Paid-in capital
4.07
5.14
49.5
78
107
121
133
143
Retained earnings
0.93
-0.14
-56
-85.8
-111
-122
-130
-140
Shareholders' equity
5
5
-6.44
-7.88
-3.71
-0.32
3.71
3.21
Minority interests
-0.22
-0.28
-0.32
-0.33
-0.33
-0.33
Total equity
5
-6.68
-6.66
-8.16
-4.03
-0.65
3.38
2.88
Total liabilities and equity
205
197
0.35
16.4
5.89
2.71
5.6
7.45
Shares outstanding
0.4
0.47
1.05
0.08
0.04
0.21
1.36
4.57
Cash flow statement
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
2.05
-1.07
-0.16
-29.1
-24.2
-10.6
-7.99
-10.2
Depreciation and amortization
0
0
0
0
0
0.01
Stock-based compensation
0.18
0.12
1.07
0.88
0.11
0.18
Deferred income tax
0
-0
Change in payables
0.32
2.34
1.18
-1.42
2.64
-1.23
-0.58
1.82
Cash from operations
-1.24
-1.42
-1.25
-8.24
-17.9
-10.8
-7.5
-7.81
Capital expenditures
-0.12
Purchases of investments
-0.57
-1.7
Cash from investing
0.84
11.9
183
0
-0.12
Debt issued
15.9
Stock issued
-11.6
-185
6.63
Share buybacks
-11.6
-185
Cash from financing
-0.03
-11
1.1
20.3
8.77
8.76
9.88
8.74
Net change in cash
-0.43
-0.6
-0.15
12.1
-9.12
-2.02
2.38
0.81
Free cash flow
-7.93
Income taxes paid
0.73
0.53
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.41 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-281.3%
Operating income / revenue.
EBITDA margin
-280.9%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-280.5%
Net income / revenue.
Operating cash flow margin
-196.8%
Cash from operations / revenue.
Return on assets (ROA)
-426.9%
Net income / average total assets.
R&D / revenue
275.2%
Research and development expense / revenue.
Stock-based pay / revenue
-0.3%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-2.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
26.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
5.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-13.3%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
33.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
8.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
84.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
266.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
497.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
18.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.70x
Current assets / current liabilities.
Quick ratio
0.17x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.17x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.35
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.68
Cash from operations / diluted weighted shares.
Book value per share
-$0.05
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.78x
Market cap / revenue.
EV/Sales
1.63x
Enterprise value / revenue.
Earnings yield
-157.4%
Net income / market cap (the inverse of P/E).
What was Ensysce Biosciences, Inc.'s revenue in fiscal 2025?
Ensysce Biosciences, Inc. reported revenue of $5.1M for fiscal 2025, 2.8% lower than the year before.
Was Ensysce Biosciences, Inc. profitable in fiscal 2025?
No. It reported a net loss of $10.2M.
How much free cash flow did Ensysce Biosciences, Inc. generate in fiscal 2025?
Cash from operations of $7.8M minus capital expenditures of $123.6K left free cash flow of -$7.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.